Aurobindo Pharma Limited
NSE: AUROPHARMA
Employs 29,209 permanent employees and workers, 5.4% on the year before, as filed for the year to 31 Mar 2026 on a group basis. Revenue in the quarter to 31 Dec 2024 was ₹2,917 cr.
Headcount
Annual, from the BRSR filed with NSE (as of 31 March each year)
| As of | Scope | Permanent | Change (%) | Contract / other | Change (%) |
|---|---|---|---|---|---|
| 31 Mar 2023 | Group | 23,451 | — | 9,962 | — |
| 31 Mar 2024 | Group | 26,015 | 2,564(10.9%) | 11,581 | 1,619(16.3%) |
| 31 Mar 2025 | Group | 27,707 | 1,692(6.5%) | 13,043 | 1,462(12.6%) |
| 31 Mar 2026 | Group | 29,209 | 1,502(5.4%) | 17,246 | 4,203(32.2%) |
Permanent = permanent employees + permanent workers, as defined in SEBI's BRSR. "Standalone" figures cover the listed company alone and exclude its subsidiaries.
Financials (₹ cr)
| Period | Revenue (₹ cr) | Change (%) | Employee cost (₹ cr) | Change (%) | Net profit (₹ cr) | Change (%) | Flags |
|---|---|---|---|---|---|---|---|
| Quarter ended 31 Dec 2024 | 2,917 | 92(3.3%) | 265 | −0(0.1%) | 472 | −66(12.2%) | |
| Quarter ended 30 Sept 2024 | 2,825 | 365(14.8%) | 266 | 6(2.4%) | 538 | 209(63.4%) | |
| Quarter ended 30 Jun 2024 | 2,460 | −434(15.0%) | 259 | 10(4.2%) | 329 | −250(43.1%) | |
| Quarter ended 31 Mar 2024 | 2,894 | 202(7.5%) | 249 | 1(0.3%) | 579 | −45(7.2%) | |
| Quarter ended 31 Dec 2023 | 2,692 | 23(0.9%) | 248 | 1(0.2%) | 624 | 208(50.1%) | |
| Quarter ended 30 Sept 2023 | 2,669 | 278(11.6%) | 248 | 11(4.8%) | 416 | 80(23.7%) | |
| Quarter ended 30 Jun 2023 | 2,391 | −1,157(32.6%) | 236 | −171(42.0%) | 336 | −309(47.9%) | |
| Quarter ended 31 Mar 2023 | 3,547 | 115(3.4%) | 407 | −12(2.8%) | 645 | 346(115.8%) | |
| Quarter ended 31 Dec 2022 | 3,432 | 545(18.9%) | 418 | 32(8.3%) | 299 | −503(62.7%) | |
| Quarter ended 31 Mar 2022 | 2,887 | 264(10.1%) | 386 | −7(1.8%) | 802 | 562(234.5%) | ⚠ |
| Quarter ended 31 Dec 2021 | 2,623 | −260(9.0%) | 394 | 4(1.1%) | 240 | 42(21.3%) | ⚠ |
| Quarter ended 30 Sept 2021 | 2,883 | −11(0.4%) | 389 | −41(9.6%) | 198 | −17(8.1%) | ⚠ |
| Quarter ended 30 Jun 2021 | 2,894 | −1,220(29.7%) | 431 | −14(3.1%) | 215 | −658(75.3%) | ⚠ |
| Quarter ended 31 Mar 2021 | 4,114 | 403(10.9%) | 445 | 14(3.2%) | 873 | 132(17.8%) | ⚠ |
| Quarter ended 31 Dec 2020 | 3,711 | −813(18.0%) | 431 | 4(1.1%) | 741 | −61(7.6%) | ⚠ |
| Quarter ended 30 Sept 2020 | 4,524 | 1,105(32.3%) | 427 | 2(0.4%) | 802 | 87(12.2%) | ⚠ |
| Quarter ended 30 Jun 2020 | 3,420 | −201(5.5%) | 425 | −0(0.1%) | 715 | −10(1.4%) | ⚠ |
| Quarter ended 31 Mar 2020 | 3,620 | 275(8.2%) | 425 | 40(10.4%) | 725 | 306(73.0%) | ⚠ |
| Quarter ended 31 Dec 2019 | 3,346 | 124(3.9%) | 385 | 11(2.9%) | 419 | 21(5.3%) | ⚠ |
| Quarter ended 30 Sept 2019 | 3,222 | −26(0.8%) | 374 | 24(6.9%) | 398 | −65(14.1%) | ⚠ |
| Quarter ended 31 Dec 2018 | 3,248 | 78(2.5%) | 350 | 18(5.4%) | 464 | 83(21.7%) | ⚠ |
| Quarter ended 30 Sept 2018 | 3,170 | 816(34.6%) | 332 | 14(4.5%) | 381 | 73(23.6%) | ⚠ |
| Quarter ended 31 Mar 2018 | 2,355 | — | 317 | — | 308 | — | ⚠ |